Market revenue in 2023 | USD 24.7 million |
Market revenue in 2030 | USD 26.6 million |
Growth rate | 1.1% (CAGR from 2023 to 2030) |
Largest segment | Oseltamivir phosphate |
Fastest growing segment | Baloxavir Marboxil |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Peramivira, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate |
Key market players worldwide | Novartis AG ADR, Roche Holding AG, BioCryst Pharmaceuticals Inc, Sanofi SA, GSK PLC, GSK PLC ADR, Viatris Inc, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Co Ltd, AstraZeneca PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza treatment market will help companies and investors design strategic landscapes.
Oseltamivir phosphate was the largest segment with a revenue share of 27.53% in 2023. Horizon Databook has segmented the UAE influenza treatment market based on peramivira, zanamivir, baloxavir marboxil, oseltamivir phosphate covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE influenza treatment market , including forecasts for subscribers. This country databook contains high-level insights into UAE influenza treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account